Wall Street expects a year-over-year increase in earnings on higher revenues when Ashland (ASH) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 6. O ...

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company’s abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the prese ...

Ashland Inc. (ASH) has accelerated the application of its new super wetting technology platform, which was unveiled last September. The company has commercialized the easy-wet 300 n super wetting agent for corn, soy and wheat, as well as watermelon, flowers and other produce such as bananas, lettuce and tomatoes.  Successful field trials and client pilots over the last year have validated Ashland's strategy and demonstrated its commitment to rapidly scaling high-performance, creative and sustainable technol ...

Ashland Inc. (ASH) has announced that it completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners LLC on Aug. 30, 2024. The transaction includes custom formulation and contract manufacturing capabilities for the nutrition market from production facilities in New Jersey and Utah, the United States, as well as Tamaulipas, Mexico. The financial terms of the deal were not disclosed.The nutraceuticals business has a wide range of proprietary ingredients, formulations and ma ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are t ...

Financial Data and Key Metrics Changes - Ashland's Q3 sales were approximately $544 million, roughly in line with the prior year, with a 3% reduction due to portfolio improvement initiatives [9][15] - Adjusted EBITDA for the quarter increased to $139 million, representing a 5% increase from the prior year, with an adjusted EBITDA margin of 25.6%, up from 24.4% [12][16] - Adjusted EPS for the quarter was $1.49 per share, up 21% from the prior-year quarter [16] Business Line Data and Key Metrics Changes - Personal Care sales increased by 20% to $175 million, with adjusted EBITDA rising 46% to $51 million, marking one of the most profitable quarters for this segment [18] - Specialty Additives sales declined by 1% to $150 million, but adjusted EBITDA increased by 31% to $38 million, with a recovery in adjusted EBITDA margin to 25.3% [20] - Life Sciences sales decreased by 11% to $195 million, with adjusted EBITDA down 18% to $59 million, primarily due to lower VP&D volumes [17] Market Data and Key Metrics Changes - Sales in North America, Europe, and Asia were stable to improving, while Latin America and the Middle East Africa showed weakness [15] - The regional recovery was mixed, with lower demand and increased competition in Asia, particularly affecting Specialty Additives [11] Company Strategy and Development Direction - Ashland is focused on portfolio optimization, including the sale of its nutraceutical business and reducing exposure to lower-margin segments [25][26] - The company aims to strengthen its competitive position in VP&D and HEC, with ongoing efforts to drive share gains [32][34] - Ashland continues to invest in technology platforms and new product launches to enhance growth opportunities [37][39] Management's Comments on Operating Environment and Future Outlook - Management noted that June sales were weaker than expected, a trend that continued into July, particularly affecting Specialty Additives [9][28] - The company expects Q4 sales in the range of $530 million to $540 million, with adjusted EBITDA between $130 million and $140 million, reflecting challenges in VP&D and softer market demand [30][40] - Management emphasized the importance of managing pricing and volume dynamics in a competitive environment, particularly in the VP&D segment [44][70] Other Important Information - Ashland repurchased $130 million of shares during the quarter and increased its dividend, reflecting confidence in long-term growth [12][24] - The company has a strong financial position with cash on hand of $399 million and total available liquidity of roughly $1 billion [22] Q&A Session Summary Question: Can you help us think about the 2025 bridge regarding fixed cost absorption and market growth? - Management indicated that the key issue is the VP&D and pharma share dynamics, with expectations for 2024 remaining largely unchanged except for the VP&D market share outlook [44][48] Question: What markets are seeing a downtick in demand? - Management noted that the biggest impact is in Specialty Additives, particularly coatings, with slower-than-expected growth in North America and Europe [55][56] Question: Can you size the VP&D pharma issue? - Management estimated that the VP&D issue resulted in a delta of around $14 million in Q3 compared to the prior year [64] Question: What is driving the pricing weakness in Personal Care and Specialty Additives? - Management explained that pricing dynamics are influenced by raw material deflation and competitive pressures, particularly in Asia [58][60] Question: How is the company managing the VP&D share loss? - Management stated that they are balancing pricing and volume gains, with ongoing negotiations with customers expected to impact future volumes [70][72]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-211719 (a Delaware corporation) I.R.S. No. 81-2587835 8145 Blazer Drive Wilmington, Delaware 19808 Telephone Number (302) 995-300 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks ...

Ashland Inc. (ASH) recorded third-quarter fiscal 2024 (ended Jun 30, 2024) adjusted earnings of $1.49 per share, up from $1.23 in the prior-year quarter. The bottom line surpassed the Zacks Consensus Estimate of $1.47.Sales were down 0.4% year over year to $544 million. The top line missed the Zacks Consensus Estimate of $569 million. Higher volumes within the Personal Care and Specialty Additives segments were partly offset by reduced Life Sciences volumes. Pricing was weaker than the prior-year quarter.Se ...

Core Insights - For the quarter ended June 2024, Ashland reported revenue of $544 million, a decrease of 0.4% year-over-year, with EPS at $1.49 compared to $1.23 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $569.02 million by 4.40%, while the EPS exceeded the consensus estimate of $1.47 by 1.36% [1] Revenue Performance - Revenue from Intermediates was $36 million, below the average estimate of $40.87 million, representing a year-over-year decline of 16.3% [3] - Revenue from Specialty Additives was $150 million, slightly below the average estimate of $154.91 million, with a year-over-year decrease of 1.3% [4] - Revenue from Personal Care reached $175 million, surpassing the average estimate of $162.63 million, showing a year-over-year increase of 19.9% [5] - Revenue from Life Sciences was $195 million, below the estimated $220.99 million, reflecting an 11% decline year-over-year [6] Adjusted EBITDA Performance - Adjusted EBITDA for Life Sciences was $59 million, compared to the average estimate of $67.79 million [7] - Adjusted EBITDA for Intermediates was $9 million, below the average estimate of $12.20 million [8] - Adjusted EBITDA for Specialty Additives was $38 million, exceeding the average estimate of $33.68 million [9] - Adjusted EBITDA for Personal Care was $51 million, above the average estimate of $46.67 million [10] Stock Performance - Ashland's shares have returned -3.9% over the past month, compared to a -6.7% change in the Zacks S&P 500 composite [11] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [11]